3,469
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Host–pathogen interactions upon Candida auris infection: fungal behaviour and immune response in Galleria mellonella

, ORCID Icon, , , , , , , , ORCID Icon & show all
Pages 136-146 | Received 13 Oct 2021, Accepted 08 Dec 2021, Published online: 21 Dec 2021

References

  • Du H, Bing J, Hu T, et al. Candida auris: epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16(10):e1008921.
  • Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13:e1006290.
  • Ku TSN, Walraven CJ, Lee SA. Candida auris: disinfectants and implications for infection control. Front Microbiol. 2018;9:726.
  • Chakrabarti A, Sood P. On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points. J Med Microbiol. 2021;70(3):001318.
  • Eyre D, Sheppard A, Madder H, et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med. 2018;379:1322–1331.
  • Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 2018;61(7):498–505.
  • Ruiz-Gaitán A, Martínez H, Moret AM, et al. Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. Expert Rev Anti Infect Ther. 2019;17(4):295–305.
  • Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–140. Erratum in: Clin Infect Dis. 2018;67(6):987.
  • Schelenz S, Hagen F, Rhodes J, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:5.
  • Centers for Disease Control (CDC). Antibiotic resistance threats in the United States. Centers for Disease Control; December 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
  • Kadri SS. Key takeaways from the U.S. CDC’s 2019 antibiotic resistance threats report for frontline providers. Crit Care Med. 2020;48(7):939–945.
  • Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen candida auris and other key pathogenic Candida species. mSphere. 2016;1(4):e00189–16.
  • Sherry L, Ramage G, Kean R, et al. Biofilm-Forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis. 2017;23(2):328–331.
  • Romera D, Aguilera-Correa JJ, García-Coca M, et al. The Galleria mellonella infection model as a system to investigate the virulence of Candida auris strains. Pathog Dis. 2020;78(9):ftaa067.
  • Muñoz JE, Ramirez LM, Dias LDS, et al. Pathogenicity levels of Colombian strains of Candida auris and Brazilian strains of Candida haemulonii species complex in both murine and Galleria mellonella experimental models. J Fungi (Basel). 2020;6(3):104.
  • Garcia-Bustos V, Ruiz-Saurí A, Ruiz-Gaitán A, et al. Characterization of the differential pathogenicity of Candida auris in a Galleria mellonella infection model. Microbiol Spectr. 2021: e0001321.
  • Carvajal SK, Alvarado M, Rodríguez YM, et al. Pathogenicity assessment of Colombian strains of Candida auris in the Galleria mellonella invertebrate model. J Fungi (Basel). 2021;7(6):401.
  • Hernando-Ortiz A, Mateo E, Perez-Rodriguez A, et al. Virulence of Candida auris from different clinical origins in Caenorhabditis elegans and Galleria mellonella host models. Virulence. 2021;12(1):1063–1075.
  • Forgács L, Borman AM, Prépost E, et al. Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model. Emerg Microbes Infect. 2020;9(1):1160–1169.
  • Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61(5):e02396–16.
  • Singh R, Kaur M, Chakrabarti A, et al. Biofilm formation by Candida auris isolated from colonising sites and candidemia cases. Mycoses. 2019;62(8):706–709.
  • Yue H, Bing J, Zheng Q, et al. Filamentation in Candida auris, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch. Emerg Microbes Infect. 2018;7(1):188.
  • Torres SR, Pichowicz A, Torres-Velez F, et al. Impact of Candida auris infection in a neutropenic murine model. Antimicrob Agents Chemother. 2020;64(3):e01625–19.
  • Fakhim H, Vaezi A, Dannaoui E, et al. Comparative virulence of candida auris with candida haemulonii, candida glabrata and candida albicans in a murine model. Mycoses. 2018;61(6):377–382.
  • Charroux B, Royet J. Elimination of plasmatocytes by targeted apoptosis reveals their role in multiple aspects of the Drosophila immune response. Proc Natl Acad Sci U S A. 2009;106(24):9797–9802.
  • Ruiz-Saurí A, García-Bustos V, Granero E, et al. Distribution of vascular patterns in different subtypes of renal cell carcinoma. A morphometric study in two distinct types of blood vessels. Pathol Oncol Res. 2018;24(3):515–524.
  • Garcia-Bustos V, Sebastian R, Izquierdo M, Rios-Navarro C, Bodí V, Chorro FJ, Ruiz-Sauri A. Changes in the spatial distribution of the Purkinje network after acute myocardial infarction in the pig. PLoS One. 2014;14(2):e0212096.
  • Bellemain E, Carlsen T. Antinociceptive effect of geranylgeraniol and 6α, 7β-dihydroxyvouacapan-17β-oate methyl ester isolated from Pterodon pubescens benth. BMC Pharmacol. 2010;10:1–9.
  • Bentz ML, Sexton DJ, Welsh RM, et al. Phenotypic switching in newly emerged multidrug-resistant pathogen Candida auris. Med Mycol. 2018;57(5):636–638.
  • Fan S, Yue H, Zheng Q, et al. Filamentous growth is a general feature of Candida auris clinical isolates. Med Mycol. 2021;59(7):734–740.
  • ElBaradei A. A decade after the emergence of Candida auris: what do we know? Eur J Clin Microbiol Infect Dis. 2020;39(9):1617–1627.
  • Mba IE, Nweze EI. Mechanism of Candida pathogenesis: revisiting the vital drivers. Eur J Clin Microbiol Infect Dis. 2020;39:1797–1819.
  • Ruiz G B, Ross ZK, Gow NAR, et al. Pseudohyphal growth of the emerging pathogen Candida auris is triggered by genotoxic stress through the S phase checkpoint. mSphere. 2020;5(2):e00151–20.
  • Rossoni RD, de Barros PP, Mendonça IDC, et al. The postbiotic activity of Lactobacillus paracasei 28.4 against Candida auris. Front Cell Infect Microbiol. 2020;10:397.
  • Gago S, García-Rodas R, Cuesta I, et al. Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella. Virulence. 2014;5(2):278–285.
  • García-Carnero LC, Clavijo-Giraldo DM, Gómez-Gaviria M, et al. Early virulence predictors during the Candida species-Galleria mellonella interaction. J Fungi (Basel). 2020;6(3):152.
  • Essig F, Hünniger K, Dietrich S, et al. Human neutrophils dump Candida glabrata after intracellular killing. Fungal Genet Biol. 2015;84:37–40.
  • Asai M, Sheehan G, Li Y, et al. Innate immune responses of Galleria mellonella to mycobacterium bovis BCG challenge identified using proteomic and molecular approaches. Front Cell Infect Microbiol. 2021;11:619981. http://doi.org/10.3389/fcimb.2021.619981